These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 15950718)

  • 21. Biology and treatment of nasopharyngeal cancer.
    Fandi A; Cvitkovic E
    Curr Opin Oncol; 1995 May; 7(3):255-63. PubMed ID: 7654828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
    Lo YM; Chan LY; Chan AT; Leung SF; Lo KW; Zhang J; Lee JC; Hjelm NM; Johnson PJ; Huang DP
    Cancer Res; 1999 Nov; 59(21):5452-5. PubMed ID: 10554016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implications.
    Cvitkovic E; Bachouchi M; Armand JP
    Hematol Oncol Clin North Am; 1991 Aug; 5(4):821-38. PubMed ID: 1890068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological markers in the diagnosis of histopathological types of nasopharyngeal carcinoma.
    Sam CK; Prasad U; Pathmanathan R
    Eur J Surg Oncol; 1989 Aug; 15(4):357-60. PubMed ID: 2547665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
    Wei WI; Yuen AP; Ng RW; Ho WK; Kwong DL; Sham JS
    Head Neck; 2004 Oct; 26(10):878-83. PubMed ID: 15390201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent allelic loss at the FRA3B site in endemic nasopharyngeal carcinoma: association with clinical features and Epstein-Barr virus infection.
    Deng YF; Zhou DN; Lu YD
    J Laryngol Otol; 2007 Nov; 121(11):1073-8. PubMed ID: 17359554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of nasopharyngeal carcinoma.
    Kraiphibul P; Atichartakarn V
    J Med Assoc Thai; 1992 Aug; 75(8):435-44. PubMed ID: 1300360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
    Mazeron MC
    Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.
    Lu H; Peng L; Yuan X; Hao Y; Lu Z; Chen J; Cheng J; Deng S; Gu J; Pang Q; Qin J
    Cancer Treat Rev; 2009 Jun; 35(4):345-53. PubMed ID: 19211192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis.
    Chen CL; Ou DL
    Hum Pathol; 2006 Oct; 37(10):1279-85. PubMed ID: 16949936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group.
    Yu KH; Leung SF; Tung SY; Zee B; Chua DT; Sze WM; Law SC; Kam MK; Leung TW; Sham JS; Lee AW; Au JS; Hui EP; Sze WK; Cheng AC; Yau TK; Ngan RK; Wong FC; Au GK; Chan AT;
    Head Neck; 2005 May; 27(5):397-405. PubMed ID: 15726589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The management of neck metastases in nasopharyngeal cancer.
    Wei WI; Mok VW
    Curr Opin Otolaryngol Head Neck Surg; 2007 Apr; 15(2):99-102. PubMed ID: 17413410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
    Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
    Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cancers of the cavum].
    Marandas P; Marandas N
    Rev Prat; 2000 Sep; 50(14):1556-61. PubMed ID: 11068620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment approaches to nasopharyngeal carcinoma: a review.
    Caponigro F; Longo F; Ionna F; Perri F
    Anticancer Drugs; 2010 Jun; 21(5):471-7. PubMed ID: 20124988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary tumor volume should be included in the TNM staging system of nasopharyngeal carcinoma.
    Liu D; Long G; Mei Q; Hu G
    Med Hypotheses; 2014 Apr; 82(4):486-7. PubMed ID: 24561054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
    Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
    Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.